In a report released today, Anthony Vendetti from Maxim Group maintained a Buy rating on BIO-key International Inc (Other OTC: BKYI), with a price target of $5.50. The company’s shares opened today at $2.29.
Vendetti wrote:
“Market close, BKYI reported weaker-than-expected 1Q18 revenue and GAAP EPS. The company introduced OmniPass Consumer and signed three new customers within the banking and industrial sectors. BKYI is growing its Asian footprint, expanding sales and marketing teams in Sri Lanka. The company maintained its full-year revenue guidance of $8M-$12M. Introducing 2020 estimates with revenue of $26.6M and GAAP EPS of $0.26.”
Vendetti has an average return of 13.1% when recommending BIO-key International Inc.
According to TipRanks.com, Vendetti is ranked #609 out of 4800 analysts.
BIO-key International Inc has an analyst consensus of Moderate Buy, with a price target consensus of $5.50.
See today’s analyst top recommended stocks >>
The company has a one-year high of $3.67 and a one-year low of $1.20. Currently, BIO-key International Inc has an average volume of 30.32K.
Based on the recent corporate insider activity of 17 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BKYI in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BIO-key International, Inc. engages in the development and market of fingerprint identification biometric technology and software solutions. It also delivers identification solutions and information services to law enforcement departments, public safety agencies, other government, and private sector customers.
